Navigation Links
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
Date:7/23/2009

ST. LOUIS, July 23 /PRNewswire-FirstCall/ --Sigma-Aldrich Corporation (Nasdaq: SIAL), a leading Life Science and High Technology company, reported second quarter 2009 diluted EPS of $0.68 compared to $0.70 in the second quarter of 2008. For the six months ended June 30, 2009, reported diluted EPS was $1.36, a 1.5% increase from the $1.34 reported for the first six months of 2008. Excluding the negative impact of currency, EPS would have been $0.79 and $1.60, a 12.9% and 19.4% increase for the second quarter and first six months of 2009, respectively. A reconciliation of proforma to reported EPS is on page 8.

CEO's STATEMENT:

Commenting on second quarter 2009 performance and full year 2009 expectations, Chairman, President and CEO Jai Nagarkatti said: "We are very pleased with our second quarter sales and operating performance in this challenging economic climate. We're also particularly pleased with our ability to improve profitability through continued implementation of our supply chain initiatives and other cost controls to largely offset the challenges of the current market on our sales and profit performance and the currency impact. We're continuing to add new and innovative products and services that we believe will differentiate our Company in the life science and high technology markets we serve."

Nagarkatti continued, "We've reaffirmed our sales and profit expectations for all of 2009, believing that we can repeat our first half performance for the remainder of the year, even with a continuation of the challenging market conditions. We continued to invest in new products, in sales and marketing initiatives and in facilities that are expected to enable us to achieve above-market rate organic sales growth. And we plan to continue to drive process impro
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
2. Sigma-Aldrich Introduces New Services Network Complementing Its Life Sciences Product Portfolio
3. Sigma-Aldrich Honored With CIO 100 Award for Innovative Web Research Tool, Your Favorite Gene powered by Ingenuity
4. Sigma-Aldrich Introduces Precisio(TM) Kinases for High-Throughput Screening and Kinase Profiling
5. Sigma-Aldrich to Present at the Baird 2009 Growth Stock Conference on Tuesday, May 12, 2009
6. Sigma-Aldrich to Present at the Bank of America and Merrill Lynch 2009 Healthcare Conference on Wednesday, May 13, 2009
7. Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening
8. Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
9. Sigma-Aldrich Acquires Sigal Ltda and Expands Operations in Chile
10. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
11. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November.... (Nasdaq: DCGN ) today announced that it has rece...ing in the company,s common stock will be,suspende...e filed with the,Securities and Exchange Commissio...sting on Nasdaq, unless the company files an appea...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November.... (Nasdaq: DCGN ) today announced the approval of ...tcy Court for the District of Delaware,(the "Bankr...petition for,relief under Chapter 11 of the United... , The orders issued by the Bankruptcy Co...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ...od & Drug Administration (SFDA) has approved t...its oral insulin project,(Nodlin), an innovative i...roval allows Biolaxy to initiate its first phase I... characteristic of high blood glucose and poor,met...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met ...endometrial cancer, , QUEBEC CITY, Nov. 24 /P...AQ: AEZS ; TSX: AEZ) (the "Company"), a global bi...py and oncology, today announced positive efficacy...oxic peptide conjugate, AEZS-108 (formerly AN-152)...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...orporation,announced today that it has entered int...HP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop A...n in various gastrointestinal,("GI") disorders. Sh... of,AT-1001 outside of the United States and Japan...1001 in the United States and Japan., Under the t...
...f,directors of Abbott today declared a quarterly c...ks the 336th consecutive quarterly dividend to be ...yable Feb. 15, 2008, to,shareholders of record at ...as increased its dividend payout for 35 consecutiv...er this year -- and was named to the,2007 Fortune ...
...euticals, Inc. (Nasdaq: ISIS ) today announced th...rshall, J.D. to Chief Operating Officer,effective ...Chief Financial,Officer, and is a Director of the ...ppropriately reflects the scope,of Lynne,s respons...,Ph.D., Isis, President and CEO. "Lynne has been a...
Other Biology Technology:Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 2Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 3Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3
(Date:11/25/2009)...isch, Head of the Cell Death Research Laboratory i... has been awarded the prestigious Johnson & Johnso... the cause of brain cell damage in Parkinson,s dis...entists in support of innovation and excellence in...nferred earlier this month at an event at the Hyat...
(Date:11/25/2009)...University assistant professors recently received ... to continue research beneficial to understanding ..., Christopher Blackwood, assistant professor in ... grants to support two separate research projects....Decomposer Communities and Functions from the Leaf...
(Date:11/24/2009)...rch Institute (LRI) today named 12 new grant recip... recognize innovative work across a broad spectrum...eativity, novelty, and potential to drive scientif...e the complex disease of systemic lupus. , The 2...searchers across the nation and include interdisci...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Schofield Media Names Brian Reshefsky Group President 56972 1Coast Dental Deploys Demandforce D3 Communications Platform 56970 1Coast Dental Deploys Demandforce D3 Communications Platform 56970 2Discovery May Pave Way to Better Diabetes Care 56967 1
...lephants dont carry photo identification, so scien...ndias Nature Conservation Foundation are providing...phic archive of individual elephants, which can he...veloped a unique photographic capture-recapture su...nts, specifically by the shape and size of their t...
...Antonio)Its been more than 100 years since anyone ...sen Sea, but that is about to change. Next month ...ence teacher will join a crew of 22 researchers fr...pedition. , The trip, funded by a $533,000 Natio...A, is designed to study the relationship of sea ic...
...sts have discovered a key protein in the toxic bra...yndrome (FXTAS), an inherited neurodegenerative di...of FXTAS, could help unravel the complex mechanism...s to target the protein. The research will be pub... , Fragile X tremor/ataxia syndrome was first rec...
Other Biology News:Male elephants get 'photo IDs' from scientists 2Texas researchers and educators head for Antarctica 2Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA 2
...,• High specific activity and processivity r...erhang ,• Processes ,A thermostable DNA...rimer extension and other molecular biology applic...lot has been functionally tested for maximal activ...
...,• High specific activity and processivity r...verhang ,• Processes ,A thermostable DN...primer extension and other molecular biology appli... lot has been functionally tested for maximal acti...
Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
Mango-Taq DNA Polymerase from Bioline
Biology Products: